Hello all! On March 18, we had 54 COPD and bronchiectasis patients, caregivers, loved ones, healthcare providers, and COPD Foundation and Bronchiectasis and NTM Association team members join us for IMPACT Lung Health 2026 in Washington, D.C. to advocate for support of our policy priorities from our lawmakers. Together, we held 101 meetings with legislative offices representing 28 states, 56 Senate districts, and 45 House districts. Bronchiectasis and NTM Association advocates spoke with lawmakers about four critical priorities:
- Support the Development of New Bronchiectasis Treatment Approaches through FY27 Appropriations Provisions
- Increase Funding for Lung Health Research and Promote Innovative Treatments through FY27 Appropriations Provisions
- Co-sponsor the Supplemental Oxygen Access Reform (SOAR) Act (H.R.2902 or S.1406) to Ensure Medicare Patients have Access to Essential Oxygen Therapy
- Co-sponsor H.R.783 or S.240 to Enact Permanent Medicare Coverage for Virtual Pulmonary Rehabilitation

We are incredibly proud of our team of advocates and the progress we made together for lung health in Washington, D.C.! If you'd like to virtually support IMPACT 2026, you can urge your lawmakers to support our policy priorities by visiting our Advocacy Action Center: https://www.votervoice.net/COPD/Campaigns/135958/Respond

We want to extend a special thank-you to our sponsors who made IMPACT 2026 possible! Thank you Boehringer Ingelheim, Chiesi USA, Inc., Insmed Incorporated, Sanofi/Regeneron, Theravance Biopharma US, Inc., and Viatris. Your support is greatly appreciated!